Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service

Background Early data suggest that patients undergoing salvage chemotherapy for relapsed or refractory (R/R) acute myeloid leukaemia (AML) have poor outcomes if infected with SARS-CoV-2, and nosocomial transmission has been a major problem worldwide. Gilteritinib is effective in R/R FLT3 mutated AML...

Descripción completa

Detalles Bibliográficos
Autores principales: Othman, Jad, Afzal, Usman, Amofa, Ruebina, Austin, Michael J, Bashford, Alex, Belsham, Edward, Byrne, Jennifer, Coats, Thomas, Dang, Raymond, Dennis, Mike, Dhawan, Saniya, Elliot, Johnathon, Francis, Sebastian, Gallipoli, Paolo, Hodgson, Katherine, Kallmeyer, Charlotte, Jain, Manish, Katsomitrou, Vana, Khan, Anjum, Khwaja, Asim, Kolade, Seye, Krishnamurthy, Pramila, Latif, Annie, Laurie, John, Lim, Michael, Loke, (Justin) Ching Ting, Manson, Cara, Marshall, Scott R., Mobashwera, Behnaz, Munisamy, Sreetharan, Murray, Duncan, Murthy, Vidhya, Palanicawandar, Renuka, Saunders, Jamie, Smith, Matthew, Smith, Katherine, Sternberg, Alex, Taussig, David, Taylor, Tom, Freeman, Sylvie D, Craddock, Charles, Dillon, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
615.Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701477/
http://dx.doi.org/10.1182/blood-2021-150169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701477/
http://dx.doi.org/10.1182/blood-2021-150169

Ejemplares similares